Last reviewed · How we verify
CG200745
At a glance
| Generic name | CG200745 |
|---|---|
| Also known as | No specific generic name yet |
| Sponsor | CrystalGenomics, Inc. |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Multiple Ascending Dose Study of CG200745 'Ivaltinostat' Oral Capsule (PHASE1)
- Phase 1/2 Study of CG200745 PPA for Myelodysplastic Syndrome (PHASE1, PHASE2)
- Pharmacokinetics and Safety of 'CG-745 IV' and 'CG-750' in Healthy Male Adults (PHASE1)
- Study of CG200745 PPA in Combination With Gemcitabine and Erlotinib for Advanced Pancreatic Cancer (PHASE1, PHASE2)
- Examine Maximum Tolerated Dose and Pharmacokinetic and Pharmacodynamic Profile (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- CG200745 CI brief — competitive landscape report
- CG200745 updates RSS · CI watch RSS
- CrystalGenomics, Inc. portfolio CI